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Abstract
Background: Controlling retinoblastoma with seeding is challenging despite advances in treatment modalities.
Intravitreal melphalan is an alternative to external beam radiation or enucleation for recurrent or refractory vitreous
seeds. Significant ocular side effects following intravitreal melphalan injections are uncommon. Complications have
been reported in eyes receiving higher concentrations of melphalan and repetitive injections. We report a case in
which diffuse chorioretinal atrophy was developed at the injection site after a single, standard low-dose intravitreal
melphalan injection.
Case presentation: A 12-month-old female child without a family history of retinoblastoma presented with
unilateral group C retinoblastoma in her right eye. A solitary tumour with retinal breaks on the tumour surface, and
vitreous seeds overlying the tumour were observed at the 8 o’clock position of the retina. After two cycles of
intra-arterial chemotherapy with melphalan, the main tumour displayed significant regression, but the vitreous
seeds overlying the main tumour were still active. Because of the persistence of vitreous seeds and the inadequate
response to intra-arterial melphalan treatment, intravitreal melphalan (8 μg in 0.05 mL) was injected using a
32-gauge needle 2.5 mm from the 5 o’clock position of the limbus, the meridian opposite to the vitreous seeds.
After 1 month, the retina around the injection site demonstrated diffuse retinal pigment epithelium alterations with
dense hard exudates. Although the main retinal mass, and vitreous seeds resolved, the hard exudates persisted for
more than 2 years after the single low-dose melphalan injection.
Conclusions: Intravitreal melphalan injections should be cautiously used for eyes with refractory seeds, particularly
when multiple injections are required to control retinoblastoma seeds. Dose- related retinal toxicity could occur in
pre-treated eyes even when a relatively low standard dose is used. Such patients should be followed up closely to
monitor the treatment response and to assess potential delayed toxicity.
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Background
Eye preservation and tumour control in patients with
retinoblastoma with seeding are challenging despite ad-
vances in treatment modalities. Treatment modalities
for vitreous seeding include external beam radiotherapy,
brachytherapy, systemic chemotherapy, intra-arterial
chemotherapy, intravitreal chemotherapy or a combin-
ation of these therapies [1–3]. Intravitreal melphalan is
an alternative to external beam radiotherapy or enucle-
ation for recurrent or refractory vitreous seeds because
it can achieve a globe salvage rate of 87–100 % [2, 3].
Although significant ocular side effects following intra-
vitreal melphalan injections are uncommon, iris atro-
phy, chorioretinal atrophy, vitreous haemorrhage and
retinal detachment have been reported. These complica-
tions are more common in eyes receiving a higher
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concentration of melphalan and repetitive injections
[4, 5]. Here, we report a case in which diffuse chorioretinal
atrophy was developed at the injection site after a single-
low dose (8 μg) intravitreal melphalan injection that suc-
cessfully controlled vitreous seeding.
Case presentation
A 12-month-old female without a family history of ret-
inoblastoma presented with unilateral group C retino-
blastoma in her right eye. A solitary tumour with retinal
breaks on the tumour surface was observed at the 8
o’clock of the retina. Vitreous seeds overlying the tumor
were also observed (Fig. 1a). After two cycles of intra-
arterial chemotherapy with 5 mg melphalan (Alkeran,
GlaxoSmithKline, Italy), the main tumour displayed sig-
nificant regression but the vitreous seeds overlying the
tumour were still active (Fig. 1b). Because of the persist-
ence of vitreous seeds and the inadequate response to
intra-arterial melphalan treatment, intravitreal melpha-
lan (8 μg in 0.05 mL) was injected using a 32- gauge
needle 2.5 mm from the 5 o’clock position of the limbus,
the meridian opposite to the vitreous seeds. Cryotherapy
was applied at the injection site, and the eye was moved
in all directions for several times to improve drug distri-
bution as previously described [6]. The main retinal
mass exhibited further regression, and all vitreous seeds
were resolved without further treatment and displayed
no recurrence. However, 1 month after the intravitreal
injection, the retina around the injection site demon-
strated diffuse retinal pigment epithelium alterations
with dense hard exudates (Fig. 2a and b). At the 3-year
follow-up, her best corrected vision is 20/60, the exu-
dates partially resolved but diffuse chorioretinal atrophy
persisted after the single low-dose of melphalan injection
(Fig. 2c and d).
Discussion
Recurrent or refractory seeds are avascular, and resistant to
conventional chemotherapy because of the hypoxic envir-
onment of the vitreous seeds. Hence, Intravitreal chemo-
therapy is an alternative to external beam radiotherapy or
enucleation for such seeds. Intra-arterial chemotherapy
and direct injection of chemotherapeutic agents, or a
combination of these therapies deliver higher chemother-
apy drug concentrations fort vitreous seeding treatment,
and have less systemic toxicity. The main concerns of
intravitreal chemotherapy are tumour spread from the
needle tract, and other potential side effects such as en-
dophthalmitis, vitreous haemorrhage and retinal toxicity
from chemotherapeutic agents. Melphalan is a cytotoxic
alkylating agent that inhibits both DNA and RNA synthe-
sis. It was originally used to treat multiple myeloma and
ovarian cancer. Intravitreal melphalan for vitreous seedings
was first introduced in the 1990s by Kaneko and Suzuki
[7]. Inomata and Kaneko investigated 12 chemotherapy
drugs and found that melphalan had the highest tumorici-
dal effect [8]. Ueda et al. investigated the optimal dose of
melphalan on rabbit retina and concluded that intravitreal
10 μg melphalan did not cause histological or electro-
retinogram (ERG) changes, and that moderate ERG
changes were observed after an injection of 20 μg melpha-
lan [9]. Initially, they injected melphalan at a dose of 8 μg;
subsequently, the standard dose was increased to 16 μg,
and 24 μg was employed for eyes refractory to standard
dose after 2008. The seeds exhibited regression after a me-
dian of 3.9 injections (range, 1–25 injections). Several re-
cent studies have reported that intravitreal melphalan at
doses of 20–30 μg is safe and efficient [2, 3, 5] Shields et al.
also demonstrated that vitreous seeds were controlled after
a mean of four injections [5].
A systematic review displayed that significant ocular
side effects including extraocular extension, retinal de-
tachment, iris atrophy, chorioretinal atrophy, vitreous
haemorrhage and retinal detachment following intravit-
real melphalan injections (8–30 μg) were uncommon. In
the studies included in this review, 1287 injections were
administered to 306 eyes, 0.01 % (3/261) of patients de-
veloped iris atrophy, 0.07 % (2/295) experienced with
retinal detachment, and 0.08 % (2/261) developed chor-
ioretinal atrophy [4]. Suzuki et al. administered 1067 in-
travitreal melphalan injections to 264 eyes of 250
patients (reported as the largest cohort) between 1990
Fig. 1 a Initial presentation: a solitary tumor at the inferior temporal retina with seeds overlying the tumour (b) The main tumor displayed
significant regression, but active vitreous seeds persisted after two cycles of intra-arterial melphalan chemotherapy
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and 2011. They reported a subconjunctival tumor with
extraocular extension in only one eye. Additionally, they
reported diffuse chorioretinal atrophy in two eyes several
months after three intravitreal injections; of these eyes,
one received external beam radiotherapy and one re-
ceived intra-arterial chemotherapy [7]. Munier et al. ad-
ministered 122 injections to 23 eyes with vitreous seeds
weekly, of which 43 % developed salt and pepper retin-
opathy at injection sites [2]. They demonstrated that
complications were more common in eyes receiving a
higher concentration of melphalan and repetitive injec-
tions. Moreover, they proposed that the risk of intraocu-
lar toxicity could be minimized by injecting melphalan
at doses ≤30 μg.
In our case, the unilateral solitary retinoblastoma with
vitreous seeds was initially treated with two monthly cy-
cles of intra-arterial melphalan (5 mg); the main tumor
exhibited significant regression but the vitreous seeds
were still active. To treat seeds refractory to inta-arterial
melphalan, we injected 8 μg intravitreal melphalan. Add-
itionally, we followed the recommended guidelines for
an intravitreal melphalan injection. However, in our case
grade 2 retinal toxicity was developed after a single intra-
vitreal melphalan injection with a dose of 8 μg, a relatively
low dose [2]. We believed that diffuse chorioretinal
atrophy at the injection was due to intravitreal injection
because no signs of retinal toxicity were observed after
two cycles of intra-arterial chemotherapy. This adverse
drug reaction occured in this eye possibly because it was
more vulnerable after intra-arterial chemotherapy.
Intravitreal chemotherapy can achieve a considerably
improved eye salvage rate; therefore, we expect intravit-
real melphalan to be more commonly used as concur-
rent or adjunctive treatment for globe salvage. Although
significant ocular complications following intravitreal mel-
phalan are uncommon, unexpected retinal toxicity could
occur even when the standard dose and a careful tech-
nique are employed particularly, in eyes received multiple
treatments.
Conclusions
Intravitreal melphalan injections should be cautiously
used when multiple injections are required to control re-
current or persistent retinoblastoma seeds after treat-
ment with systemic or intra-arterial chemotherapy.
Although significant ocular side effects are uncommon,
and extraocular extension is rare, clinicians should be
aware of its cumulative effects, and its narrow thera-
peutic window. Dose related retinal toxicity could occur
in patients with pre-treated eyes even with a relatively
Fig. 2 a The main retinal tumour at the inferior temporal retina exhibited further regression. b Diffuse retinal pigment epithelial alterations and
exudates were found at the inferior nasal retina where intravitreal melphalan was injected. c and d At the 3- year follow-up, the main tumor
displayed calcified regression with partial resolved exudates and chorioretinal atrophy
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low standard dose. Such patients must be followed up
closely to monitor the treatment response and assess po-
tential delayed toxicity.
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